Open AccessMetastatic gastrointestinal stromal tumor: A regional cancer center experience of 44 cases
Author(s) -
M C Suresh Babu,
Tamojit Chaudhuri,
K Govind Babu,
K C Lakshmaiah,
Lokanatha Dasappa,
Linu Abraham Jacob,
A.H. Rudresha,
K N Lokesh,
L K Rajeev
Publication year - 2017
Publication title -
south asian journal of cancer
Language(s) - English
Resource type - Journals
eISSN - 2278-4306
pISSN - 2278-330X
DOI - 10.4103/sajc.sajc_290_16
Subject(s) - medicine , gist , imatinib , stromal tumor , gastrointestinal tract , peritoneum , chemotherapy , cancer , single center , surgery , gastroenterology , oncology , stromal cell , myeloid leukemia
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. Historically, a poor prognosis for metastatic disease has been reported with systemic chemotherapy. Significant advances have been made in the last decade, since the introduction of different tyrosine kinase inhibitors (TKIs). Unfortunately, even though the TKIs have been used for a long time, there are very few published data of the experience of TKI therapy in metastatic GIST from India.